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Interdisciplinary approach in a patient 
diagnosed with prostate cancer 
and spine metastases
Abstract
Prostate cancer is one of the malignant tumours in which treatment of bone metastases is a significant 
clinical problem. In this article 66-year-old patient diagnosed with prostate cancer and multiple metastases 
to all parts of the spine with accompanying neuropathic pain of severe intensity, which disabled self-mov-
ing of a patient is presented. The patient was not qualified for surgery during neurosurgeon consultation. 
During palliative care provision for the patient by an interdisciplinary team of Home Hospice composed 
pharmacology treatment of pain was introduced using oxycodone/naloxone, ketoprofen and adjuvant 
analgesics: zoledronate acid with calcium and vitamin D supplementation, pregabalin and dexamethasone. 
Stability of the spine was provided through high trunk orthosis in order to minimize the risk of spine dam-
age associated with rehabilitation. A significant decrease in pain, constipation and anxiety intensity was 
achieved with an improvement of overall performance status and quality of life, which enabled a further 
anticancer treatment and palliative radiotherapy. The submitted case indicates on a necessity of palliative 
care provided by the interdisciplinary team for patients diagnosed with prostate cancer and dissemination to 
bones and severe pain intensity, which significantly increases a chance for obtaining satisfactory analgesia, 
improvement in the quality of life and a possibility of continuing anticancer and symptomatic treatment.
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Introduction
The number of patients diagnosed with malignant 
tumours continues to rise along with new anticancer 
treatment possibilities, which together with  effective 
symptomatic management prolong overall survival 
[1]. Among numerous problems of contemporary 
oncology, which appear with prolonged survival, one 
of the most important is the treatment of patients 
with bone metastases, especially those with spine 
secondaries. The presence of bone metastases is 
usually an evidence of advanced stage of cancer, sig-
nificantly decrease patients’ quality of life (QoL) and 
render a possibility of the development of potential 
life–threatening skeletal–related events (SRE), such as 
pathological bone fractures, including spine, spinal 
cord compression and hypercalcemia [2].
Bone metastases are present in 30–50% patients 
diagnosed with malignant tumors [3, 4], most fre-
quently in the course of multiple myeloma (80–100%), 
prostate (70–75%), breast (65–75%), thyroid (50%), 
lung (30–40%), malignant melanoma (15–40%) and 
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renal cancer (20–25%) [5–7]. Metastases are present 
20-times more frequently compared to primary spine 
tumours [8], and the most frequent location is thoracic 
spine (70%), and less frequently lumbar and cervical 
spine [9, 10]. Regarding radiology picture, metastases 
may be divided into osteolytic and osteoblastic (osteo-
sclerotic). However, due to the reciprocal influence of 
osteoclasts and osteoblasts bone metastases have no 
uniform type (i.e. exclusively osteolytic or osteoblas-
tic). It rather may be characterized as bone metastases 
with predominant osteolytic (multiple myeloma, renal 
cancer, malignant melanoma) or predominant osteo-
blastic (prostate and breast cancer) [11].
Spine metastases significantly affect patients’ 
QoL, mainly due to severe pain limiting patients’ 
activity and performance status (PS), hypercalcemia 
symptoms, and also pathological fractures of ver-
tebral bodies and paralysis induced by spinal cord 
compression [12, 13]. In the diagnostic process, it is 
important to find out whether neurology complica-
tions are present, such as movement disturbances, 
dysesthesia and sphincter functions. In case of sudden 
and recent appearance of these symptoms, it is nec-
essary to conduct diagnostic tests and appropriate 
therapeutic intervention. In each case, however, in 
order to diminish the consequences of spine metas-
tases, maximizing patients’ PS and QoL, and achieving 
possible improvement, it is necessary to undertake 
appropriate diagnostic investigations and treatment. 
Due to the complexity of problems, most frequently 
interdisciplinary approach is required [14].
Case presentation
67-year-old patient, a farmer, fit, professional-
ly active, till 2014 did not need medical care. For 
4 years irregularly consulted in urology outpatient 
clinic due to benign prostate hyperplasia. For 3 years 
complained about pain localized in a lumbar spine, 
intensifying during movements, and relieving at rest 
when lying. In this time patient received PRN doses of 
over the counter analgesics (paracetamol, ibuprofen, 
metamizol). In November 2017 due to the intensifying 
pain patient visited a family physician who diagnosed 
back pain, probably evoked by spondylarthrosis, and 
prescribed ketoprofen 100 mg twice a day as intra-
muscular injections.
Due to the lack of analgesic effect and a change 
of the pain characteristics (radiation to thighs), after 
3 weeks the patient was referred to Neurology Depart-
ment. An MRI (magnetic resonance imaging) scan was 
conducted with multiple spondylarthrosis in a majority 
of vertebral bodies with accompanying discopathy 
on levels Th1/Th2, Th2/Th3, Th8/Th9, Th12/L1, L1/L2, 
L2/L3, L3/L4, L5/S1 (without features of disco–radic-
ular conflict) and L4/L5 with narrowing of the right 
intervertebral foramen and pressure on nerve roots. In 
all thoracic and lumbar vertebra and in sacral bone 
multiple foci of different size have been shown, which 
underwent heterogenous reinforcement after contrast 
administration – a picture of metastases. The height 
of the vertebral bodies was preserved.
Additionally, enlarged lymph nodes were demon-
strated in the retroperitoneal space. In an X–ray of 
hips coxarthrosis with both sides sub–cartilage scle-
rotization and narrowing of a joint aperture at the 
right side. The chest X-ray was normal. Concurrently 
PSA (Prostate Specific Antigen) was assayed with 
significantly risen values (total PSA > 100.0 ng/mL; 
free PSA > 50.0 ng/mL). Prostate cancer with spine 
metastases was diagnosed. The patient was consulted 
by a neurosurgeon who disqualified the patient from 
a neurosurgical intervention.
The pain was treated with transdermal buprenor-
phine in the dose of 35 µg/h, every 3 days and PRN 
1–3 tablets per day of paracetamol with tramadol 
(325 mg + 37.5 mg, respectively). Additionally, dex-
amethasone 4 mg twice daily IV was administered. 
Patient with a slight improvement in analgesia ac-
cording to NRS (Numerical Rating Scale) 6–7 was dis-
charged home with a recommendation of continuing 
analgesic regimen and conducting prostate biopsy in 
Urology Department and consultation in Oncology 
Outpatient Clinic.
Due to severe pain, intensifying confusion, and 
intense constipation patient was again consulted at 
home by family physician who stopped buprenor-
phine, and reinstituted ketoprofen 100 mg and dex-
amethasone 4 mg (both drugs administered orally 
twice daily), increased the dose of tramadol with 
paracetamol to 3 times daily 75 mg + 650 mg, re-
spectively, and recommended glycerin suppositories 
PRN rectally and omeprazole 20 mg once daily orally. 
Due to lack of improvement patient himself increased 
a dose of ketoprofen till 100 mg 3–4 times a day, and 
additionally took ibuprofen 200 mg up to 3 times 
a day, metamizol 500 mg twice a day and paracetamol 
500 mg 2–3 times a day orally. In Urology outpatient 
clinic prostate biopsy was conducted, histopathology: 
adenocarcinoma (Gleason 4 + 4).
At the time of starting palliative care at home 
(Home Hospice) the patient in general was in a quite 
poor condition. Due to severe pain patient’s activity 
was significantly limited: PS according to Karnofsky 
40 and ECOG 3–4 [15]. Pain according to NRS (pain 
right now and average pain within last 2 weeks) 
9–10. The pain was localized in lumbar region depicted 
as burning, radiating to both lower extremities with 
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characteristics similar to electric shock-like sensations 
along the spine, which intensified during each activity 
— the patient was unable to stand up due to the pain. 
Physical examination showed limited movements of 
lower extremities induced by pain without radicular 
symptoms, weakness of proximal muscles and hyper-
esthesia of the skin of anterior surface of thighs, pre-
dominantly at the right side. PainDetect questionnaire 
result was 30/38, which confirmed a neuropathic pain 
component [16]. HADS–M (Hospital Anxiety and De-
pression Scale — Modified Version) result: depression 
6/21, anxiety 15/21 — anxiety disorders [17].
Pain was managed with oxycodone/naloxone, 
starting from a dose of 10 mg + 5 mg, every 12 h, 
subsequently with good treatment tolerance the dose 
was increased, every few days in the following order: 
20 mg + 10 mg, every 12 h → 30 mg + 15 mg, every 
12 h → 40 mg + 20 mg, every 12 h. Ketoprofen 
administered orally at a dose of 100 mg was contin-
ued. Concurrently, pregabalin as a co-analgesic was 
introduced in the form of capsules, starting at 75 mg 
before sleep for 7 days, increasing the dose, every 
7 days by 75 mg (75 mg/at night → 75 mg twice dai-
ly → 75 mg in the morning; 150 mg at night → 150 mg 
twice daily).  Morphine sulfate immediate – release 
(IR) orally was used as a rescue analgesic, starting 
with a dose of 10 mg, increased to 20 mg, most often 
60 minutes before planned hygienic procedures and 
rehabilitation. Dexamethasone was continued with 
tapering the dose to 2 mg twice daily, omeprazole 
was substituted with esomeprazole at a dose of 
40 mg once daily (both drugs administered orally). 
Constipation was additionally treated with lactulose 
20 ml three times daily. A significant improvement 
in analgesia and PS was achieved and after 2 weeks 
the pain intensity right now and pain on average 
according to NRS equaled 3–4, and the patient was 
able to walk without assistance at his house, using 
PRN 1–2 tablets of 20 mg of IR morphine sulphate 
per day, with improvement in anxiety. The patient had 
spontaneous bowel movements every 2 days.
Concurrently, zoledronic acid was introduced at 
a dose of 4 mg every 21 days intravenously with vita-
min D (2000 U per day) and calcium (400 mg calcium 
carbonate daily) supplementation, with surveillance of 
creatinine and ionized calcium concentrations in the 
blood serum. The first administration of the drug-in-
duced para–flu symptoms – treatment comprised 
oral administration of paracetamol 500 mg 3 times 
daily for 2 days with good effect. After achieving 
satisfactory analgesia, dexamethasone was tapered 
to 2 mg in the morning. The patient was referred 
for a consultation to Radiotherapy Unit for palliative 
radiotherapy of the lumbar spine.
Discussion
The presented patient was a farmer, working on his 
own farm, and interpreted the occurrence of his pain 
as a consequence of straining associated with physical 
effort, as the pain intensified during movement and 
relieved at rest. Until the pain was not too severe and 
limited to a spine area, the patient took over the coun-
ter analgesics and when lacking their efficacy at a next 
stage — drugs prescribed by a family physician. Only 
the appearance of severe pain disabling movements 
with radiation to lower extremities and accompanying 
weakness of muscle strength of lower extremities was 
a reason for hospital admission and conducting MRI 
scan. A weakness of muscle strength is the second 
most frequent symptom present in 35–75% of patients 
diagnosed with spine metastases at the moment 
of diagnosis [18]. Usually, patients complain about 
a feeling of heaviness in extremities, and in physical 
examination motor deficits are found which may be 
accompanied with dysesthesia, although a function 
of sphincters may still be preserved in earlier stages 
of spinal cord compression [19].
Pain may have different characteristics, but is one 
of the most frequent symptoms of spine metastases 
and is present in approximately 90% of patients 
[20]. Pain usually intensifies during palpation and 
percussion, and it may also resemble radicular pain 
induced by  pressure on spinal nerve roots, or it may 
display pain exacerbated by movement and alleviated 
by rest [21, 22]. Such diversity of pain characteristics 
is often the reason that patients are for a long time 
treated by family physicians, orthopedists, or neu-
rologists with an assumption that a cause of a back 
pain is spondylarthrosis or discopathy, especially if in 
the medical history cancer was not diagnosed and 
patient is an active person who matches symptoms 
with excessive physical straining.
Diagnosis of bone metastases is possible with 
using several methods of imaging. X-ray is often 
a preliminary screening test because of common avail-
ability and low cost. A negative result, however, does 
not exclude the presence of bone metastases, which 
are clearly visible just after the destruction of nearly 
half of vertebral body [23]. Computed tomography 
(CT) is useful in the assessment of bone elements 
of the spine, including osteolytic or osteosclerotic 
changes, also a compressive fracture of the vertebral 
body. Main disadvantages of CT refer to the inability 
of differentiation of soft tissues and the necessity of 
contrast administration in the technic of myelography 
to show subarachnoid space; it is the reason why it 
is possible to show only 50% of changes in epidural 
space and in soft tissues [24]. A precise method of 
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spine metastases diagnosis is MRI, which allows on 
multidimensional imaging in high fidelity of all spine 
elements, including bone structures and also for the 
differentiation of soft tissues, which enables to show 
the spinal cord, radicular nerves, intervertebral discs 
and paravertebral muscles. Bone scintigraphy and 
other isotope investigations such as positron emis-
sion tomography (PET) or single-photon emission 
computed tomography (SPECT) in imaging of bone 
metastases [25] should be also mentioned, although 
these are less available in Poland. After diagnosing 
of multiple spine metastases in case of presence of 
neurology symptoms urgent neurosurgeon consulta-
tion is recommended [26]. The depicted patient was 
disqualified from a neurosurgical intervention.
During the patient’s stay in a hospital, pain was 
treated with buprenorphine and a composite product 
containing tramadol and paracetamol without any ef-
fect. Such treatment with concurrent use of analgesics 
from all steps of the WHO analgesic ladder (paraceta-
mol, NSAIDs, tramadol and buprenorphine), usually is 
not practised [27]. In the depicted patient, these drugs 
induced adverse effects (AE): confusion and constipa-
tion. Despite the fact that buprenorphine belongs to 
the strong opioids preferred in older patients as well 
as in the treatment of neuropathic pain [28], due to 
lack of satisfactory analgesia and appearance of AE 
the treatment was terminated. Another strong opioid 
which possesses evidenced efficacy in the treatment 
of chronic pain in cancer patients with neuropathic 
pain component is oxycodone [29]. However, due to 
the history of chronic constipation, oxycodone was 
used with naloxone [30], which allowed to relieve 
both pain and constipation. Treatment with keto-
profen was continued, and due to neuropathic pain 
component, pregabalin was added as a co–analgesic 
recommended in the management of this type of pain 
by the Polish Association for the Study of Pain and the 
Polish Association of Neurology [31, 32]. Due to the 
age of the patient the dose of pregabalin was carefully 
titrated with increments in doses every 7 days, which 
allowed avoiding AE.
Further improvement in analgesia with a decrease 
of intensity of concurrent generalized anxiety, which 
may be matched with an additional anxiolytic effect 
of pregabalin, was observed [33]. In connection with 
an improvement and lack of symptoms of depression 
in HADS-M, antidepressants (venlafaxine, duloxetine) 
were not used, which are also recommended in the 
treatment of patients diagnosed with neuropathic 
pain [31, 34]. Dexamethasone which was instituted at 
Neurology Department was continued with a gradual 
decrease of the dose. Such an approach was sup-
ported by a high probability of  local activation of 
spinal nerve roots by metastases to vertebral bodies, 
which was based on symptoms and results of imag-
ing investigations [35]. Because dexamethasone was 
co–administered with ketoprofen,  prophylaxis was 
instituted with proton pump inhibitor (omeprazole, 
which was due to a lower risk of drug interactions 
subsequently substituted with esomeprazole) [36].
Bone metastases increase the risk of appearance 
of SRE [37]. SRE in the course of prostate cancer ap-
pear with the following frequency: radiotherapy 33%, 
pathological fractures 25%, hypercalcemia 25%, spinal 
cord compression 8% and the necessity of surgical 
intervention 4% (combined frequency of SRE equals 
49%) [38]. Bisphosphonates display anticancer prop-
erties through blocking signal transmission between 
cancer cells and bone cells [39]. Bisphosphonates also 
prolong TTSRE (time to skeletal–related event) and 
prevent the appearance of SRE [40]. In the depicted 
patient a treatment with zoledronic acid was institut-
ed intravenously and supplementation with calcium 
and vitamin D given by oral route. Additionally, due 
to a rehabilitation of the patient, high trunk orthosis 
was used to decrease the risk of SRE.
In a study that was a base for registration of zole-
dronic acid for the treatment of patients diagnosed 
with prostate cancer and bone metastases, apart from 
anticancer treatment, zoledronate was administered 
intravenously at a dose of 4 mg or placebo every 
21 days [40]. The primary outcome of the study was 
the frequency ratio of SRE in both patient groups 
during 15 months of the treatment. Significantly 
less SRE were found in the group of patients treated 
with zoledronate compared to those receiving pla-
cebo (33% vs. 44%). Similarly, patients treated with 
zoledronate had significantly longer time (median) to 
the first SRE (488 days vs. 321 days). Apart from the 
aforementioned benefits the use of zoledronate was 
associated with less pain intensity as well as coun-
teracted the development of osteoporosis, already 
present or induced by corticosteroids and hormone 
manipulations [41].
Among AE of bisphosphonates administered 
through intravenous route should be listed electro-
lyte imbalance (most frequently hypocalcemia), renal 
function disturbances, jaws necrosis, and transient 
flu–like symptoms, which appear most often after the 
first administration of the drug. During the treatment 
with bisphosphonates should be conducted appropri-
ate fluid supply, supplementation with vitamin D and 
calcium, and assays of electrolytes, especially ionized 
calcium and eGFR before each bisphosphonate ad-
ministration [42–44]. Before starting treatment with 
bisphosphonates a dentist consultation is required, 
and any necessary stomatology treatment should be 
www.journals.viamedica.pl/palliative_medicine_in_practice 211
Marek Widenka, Wojciech Leppert, Interdisciplinary approach in a patient diagnosed with prostate cancer and spine metastases
instituted. During bisphosphonates treatment teeth 
extraction, implants institution, and other stomatol-
ogy and facial–jaw surgical interventions should be 
avoided. Regular dental control every 3–4 months is 
recommended  during bisphosphonate therapy [45].
Radiotherapy (RT) is deemed method of treatment 
of patients diagnosed with spine metastases. The 
aim of RT is to decrease pain intensity, improvement 
of patients’ QoL and maintaining or improvement of 
bone system function. RT benefits concerning pain 
relief may be observed within a period of a few days to 
a few weeks, which should be considered in optimizing 
pharmacology treatment [46]. Apart from bone pain, 
other indications for RT in patients diagnosed with 
spine metastases comprise imminent or symptoms 
of spinal cord compression, threat or appearance of 
pathological fracture after surgical treatment. In the 
case of spine metastases transdermal vertebroplasty 
combined with complementary RT seems to be more 
beneficial compared to RT used alone in order to relieve 
pain, maintain the stability of the spine and improving 
patients’ QoL [47]. Contraindications to RT are asso-
ciated with a dose of former irradiation tolerated by 
critical organs, and in consequence lack of the possi-
bility to repeat irradiation of a given location, which 
mainly refers to the spinal cord, guts, urinary bladder 
and very short (few days) predicted survival time [48].
In numerous randomized studies, similar analgesic 
efficacy of a single fraction (6–8 Gy) or multiple fractions 
(30 Gy in 10 fractions, 24 Gy in 6 fraction and 20 Gy in 
5 fractions) was demonstrated [49,50]. Analgesic effect 
of RT regardless of fractionation method is observed 
in approximately 50–85% treated patients and in 30% 
of treated patients pain completely disappears [51]. 
A complete or partial analgesic effect of RT in patients 
diagnosed with bone metastases usually appears in 
the period of 4 weeks since RT and the mean time of 
remission lasts for approximately 19 weeks [52]. The 
response rate is higher, and the remission period is 
longer in patients diagnosed with breast and prostate 
cancer compared to those diagnosed with lung and 
other primary tumour locations [53].
Another treatment method that is used inde-
pendently or in combination with local RT and other 
types of treatment in patients diagnosed with multiple 
spine metastases in the course of prostate cancer 
are radioisotopes. This treatment method is used 
in patients with osteoblastic or mixed metastases, 
sometimes before the clinical symptoms appear, which 
decrease the number of new pain areas and risk 
of pathological fractures. The use of radioisotopes 
decreases pain intensity and number of SRE and im-
proves patients’ QoL [54].
The treatment used improved overall PS and QoL 
and regained the patient self–care, which allowed 
to refer the patient for consultations and further 
treatment to Radiotherapy Unit and Urology Outpa-
tient Clinic.
Conclusions
Cancer patients with spine metastases often visit 
physicians with numerous and complex diagnostic 
and/or therapeutic problems that require integrat-
ed care. Diagnostic and therapeutic management 
requires cooperation between different specialists, 
including orthopedist, neurologist, neurosurgeon, 
radiotherapist, nuclear medicine and palliative med-
icine specialist, and also specialists for the treatment 
of cancer: urologist — prostate and renal cancer, pul-
monologist — lung cancer, haematologist — multiple 
myeloma, oncologist — other tumours. Such physi-
cians team should additionally cooperate with a nurse, 
physiotherapist, psychologist, social worker, medical 
career and a chaplain. The additional condition that is 
necessary to improve patients’ QoL, independent from 
a prognosis, is a provision of appropriate coordination 
of care and integration of proposed treatment. Such 
an interdisciplinary approach gives a chance for  better 
care for a patient in a difficult clinical situation as the 
presence of multiple spine metastases is. 
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